靶向肿瘤内皮细胞的纳米颗粒。
Targeting Tumor Endothelial Cells with Nanoparticles.
机构信息
Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, 260-8675, Chiba, Japan.
Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, 060-0812, Hokkaido, Japan.
出版信息
Int J Mol Sci. 2019 Nov 20;20(23):5819. doi: 10.3390/ijms20235819.
Abstract
Because angiogenesis is a major contributor to cancer progression and metastasis, it is an attractive target for cancer therapy. Although a diverse number of small compounds for anti-angiogenic therapy have been developed, severe adverse effects commonly occur, since small compounds can affect not only tumor endothelial cells (TECs), but also normal endothelial cells. This low selectivity for TECs has motivated researchers to develop alternate types of drug delivery systems (DDSs). In this review, we summarize the current state of knowledge concerning the delivery of nano DDSs to TECs. Their payloads range from small compounds to nucleic acids. Perspectives regarding new therapeutic targets are also mentioned.
摘要
由于血管生成是癌症进展和转移的主要贡献者，因此它是癌症治疗的一个有吸引力的靶点。尽管已经开发出了许多用于抗血管生成治疗的小分子化合物，但严重的不良反应通常会发生，因为小分子化合物不仅可以影响肿瘤内皮细胞（TECs），还可以影响正常内皮细胞。这种对 TECs 的低选择性促使研究人员开发出替代类型的药物递送系统（DDS）。在这篇综述中，我们总结了目前关于将纳米 DDS 递送到 TEC 的知识状态。它们的有效载荷范围从小分子化合物到核酸。还提到了关于新治疗靶点的观点。
相似文献
1
Targeting Tumor Endothelial Cells with Nanoparticles.靶向肿瘤内皮细胞的纳米颗粒。
Int J Mol Sci. 2019 Nov 20;20(23):5819. doi: 10.3390/ijms20235819.
2
Heterogeneity of tumor endothelial cells and drug delivery.肿瘤内皮细胞异质性与药物传递。
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt B):140-147. doi: 10.1016/j.addr.2015.11.008. Epub 2015 Nov 26.
3
Nanoparticle-mediated delivery of anticancer agents to tumor angiogenic vessels.纳米颗粒介导的抗癌药物递送至肿瘤血管生成血管。
Biol Pharm Bull. 2012;35(11):1855-61. doi: 10.1248/bpb.b212013.
4
Contribution of Tumor Endothelial Cells in Cancer Progression.肿瘤内皮细胞在癌症进展中的作用。
Int J Mol Sci. 2018 Apr 24;19(5):1272. doi: 10.3390/ijms19051272.
5
Targeting prion-like protein doppel selectively suppresses tumor angiogenesis.靶向朊病毒样蛋白多配体可选择性抑制肿瘤血管生成。
J Clin Invest. 2016 Apr 1;126(4):1251-66. doi: 10.1172/JCI83427. Epub 2016 Mar 7.
6
Peptide-Conjugated Nanoparticles as Targeted Anti-angiogenesis Therapeutic and Diagnostic in Cancer.肽修饰的纳米颗粒作为癌症靶向抗血管生成治疗和诊断的研究进展
Curr Med Chem. 2019;26(30):5664-5683. doi: 10.2174/0929867326666190620100800.
7
Dendrimer-mediated targeting of angiogenic biomarkers: therapeutic intervention against cancer.树状高分子介导的血管生成生物标记物靶向：癌症治疗干预。
Expert Opin Drug Deliv. 2024 Aug;21(8):1235-1250. doi: 10.1080/17425247.2024.2394631. Epub 2024 Sep 4.
8
Angiogenesis regulation by nanocarriers bearing RNA interference.纳米载体通过 RNA 干扰调节血管生成。
Adv Drug Deliv Rev. 2017 Sep 15;119:3-19. doi: 10.1016/j.addr.2017.01.008. Epub 2017 Feb 2.
9
Cell-Based Nanoparticles Delivery Systems for Targeted Cancer Therapy: Lessons from Anti-Angiogenesis Treatments.基于细胞的纳米颗粒递药系统用于靶向癌症治疗：抗血管生成治疗的经验教训。
Molecules. 2020 Feb 7;25(3):715. doi: 10.3390/molecules25030715.
10
Recent Advances and Strategies in Tumor Vasculature Targeted Nano-Drug Delivery Systems.肿瘤血管靶向纳米药物递送系统的最新进展与策略
Curr Pharm Des. 2015;21(22):3066-75. doi: 10.2174/1381612821666150531163047.
引用本文的文献
1
Targeting endothelial MYC using siRNA or miR-218 nanoparticles sensitizes chemo- and immuno-therapies by recapitulating the Notch activation-induced tumor vessel normalization.使用小干扰RNA（siRNA）或miR-218纳米颗粒靶向内皮细胞中的MYC，通过重现Notch激活诱导的肿瘤血管正常化，使化学疗法和免疫疗法更敏感。
Theranostics. 2025 Apr 13;15(11):5381-5401. doi: 10.7150/thno.112023. eCollection 2025.
2
Angiogenesis and targeted therapy in the tumour microenvironment: From basic to clinical practice.肿瘤微环境中的血管生成与靶向治疗：从基础到临床实践
Clin Transl Med. 2025 Apr;15(4):e70313. doi: 10.1002/ctm2.70313.
3
Exploring the synergy between tumor microenvironment modulation and STING agonists in cancer immunotherapy.探索肿瘤微环境调节与STING激动剂在癌症免疫治疗中的协同作用。
Front Immunol. 2024 Dec 6;15:1488345. doi: 10.3389/fimmu.2024.1488345. eCollection 2024.
4
Targeted anti-angiogenesis therapy for advanced osteosarcoma.晚期骨肉瘤的靶向抗血管生成治疗
Front Oncol. 2024 Aug 26;14:1413213. doi: 10.3389/fonc.2024.1413213. eCollection 2024.
5
Therapeutic Strategies to Overcome Fibrotic Barriers to Nanomedicine in the Pancreatic Tumor Microenvironment.克服胰腺肿瘤微环境中纳米医学纤维化障碍的治疗策略。
Cancers (Basel). 2023 Jan 24;15(3):724. doi: 10.3390/cancers15030724.
6
Recent advances of nanomaterial-based anti-angiogenic therapy in tumor vascular normalization and immunotherapy.基于纳米材料的抗血管生成疗法在肿瘤血管正常化和免疫治疗方面的最新进展
Front Oncol. 2022 Nov 29;12:1039378. doi: 10.3389/fonc.2022.1039378. eCollection 2022.
7
Cancer Stem Cells and the Tumor Microenvironment: Targeting the Critical Crosstalk through Nanocarrier Systems.癌症干细胞与肿瘤微环境：通过纳米载体系统靶向关键串扰。
Stem Cell Rev Rep. 2022 Oct;18(7):2209-2233. doi: 10.1007/s12015-022-10426-9. Epub 2022 Jul 25.
8
Tumor Microenvironment Shapes Colorectal Cancer Progression, Metastasis, and Treatment Responses.肿瘤微环境塑造结直肠癌的进展、转移及治疗反应。
Front Med (Lausanne). 2022 Mar 23;9:869010. doi: 10.3389/fmed.2022.869010. eCollection 2022.
9
Novel antiangiogenic therapy targeting biglycan using tumor endothelial cell-specific liposomal siRNA delivery system.靶向 biglycan 的新型抗血管生成治疗：利用肿瘤内皮细胞特异性脂质体 siRNA 递药系统。
Cancer Sci. 2022 May;113(5):1855-1867. doi: 10.1111/cas.15323. Epub 2022 Mar 21.
10
Functionalized Liposome and Albumin-Based Systems as Carriers for Poorly Water-Soluble Anticancer Drugs: An Updated Review.功能化脂质体和白蛋白基体系作为难溶性抗癌药物载体的最新综述
Biomedicines. 2022 Feb 18;10(2):486. doi: 10.3390/biomedicines10020486.
本文引用的文献
1
Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response.肿瘤和免疫异质性对抗癌免疫反应的影响。
Cancers (Basel). 2019 Aug 21;11(9):1217. doi: 10.3390/cancers11091217.
2
Cell-penetrating peptide: a means of breaking through the physiological barriers of different tissues and organs.细胞穿透肽：一种突破不同组织和器官生理屏障的手段。
J Control Release. 2019 Sep 10;309:106-124. doi: 10.1016/j.jconrel.2019.07.020. Epub 2019 Jul 16.
3
Advances in chitosan-based nanoparticles for oncotherapy.壳聚糖基纳米粒子在肿瘤治疗中的进展。
Carbohydr Polym. 2019 Oct 15;222:115004. doi: 10.1016/j.carbpol.2019.115004. Epub 2019 Jun 19.
4
Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma.甘胆酸脂质体剂型提高了聚乙二醇脂质体阿霉素在小鼠结肠癌细胞中的治疗效果。
Sci Rep. 2019 Jul 2;9(1):9527. doi: 10.1038/s41598-019-45974-7.
5
PEGylated immunoliposome-loaded endoglin single-chain antibody enhances anti-tumor capacity of porcine α1,3GT gene.聚乙二醇化免疫脂质体负载内皮糖蛋白单链抗体增强猪 α1,3GT 基因的抗肿瘤能力。
Biomaterials. 2019 Oct;217:119231. doi: 10.1016/j.biomaterials.2019.119231. Epub 2019 Jun 14.
6
cRGD-functionalized nanoparticles for combination therapy of anti-endothelium dependent vessels and anti-vasculogenic mimicry to inhibit the proliferation of ovarian cancer.cRGD 功能化纳米颗粒用于抗血管内皮依赖性和抗血管生成拟态的联合治疗，以抑制卵巢癌细胞的增殖。
Acta Biomater. 2019 Aug;94:495-504. doi: 10.1016/j.actbio.2019.06.039. Epub 2019 Jun 25.
7
Recent Advances in Aptamer Discovery and Applications.近年来适体发现与应用的新进展
Molecules. 2019 Mar 7;24(5):941. doi: 10.3390/molecules24050941.
8
Vascular targeted chitosan-derived nanoparticles as docetaxel carriers for gastric cancer therapy.血管靶向壳聚糖衍生纳米粒作为多西紫杉醇载体用于胃癌治疗。
Int J Biol Macromol. 2019 Apr 1;126:662-672. doi: 10.1016/j.ijbiomac.2018.12.262. Epub 2018 Dec 29.
9
Effective Therapy Using a Liposomal siRNA that Targets the Tumor Vasculature in a Model Murine Breast Cancer with Lung Metastasis.在具有肺转移的小鼠乳腺癌模型中，使用靶向肿瘤血管的脂质体小干扰RNA进行有效治疗。
Mol Ther Oncolytics. 2018 Oct 30;11:102-108. doi: 10.1016/j.omto.2018.10.004. eCollection 2018 Dec 21.
10
Lipocalin 2: a potential therapeutic target for breast cancer metastasis.脂质运载蛋白2：乳腺癌转移的潜在治疗靶点。
Onco Targets Ther. 2018 Nov 13;11:8099-8106. doi: 10.2147/OTT.S181223. eCollection 2018.
Zotero 插件